CTRI/2019/07/019996
Recruiting
Phase 4
A prospective, open-label, multicenter, phase IV clinical study to evaluate the long term persistence of immunological response after primary vaccination with Typhoid Vi Conjugate Vaccine and response to booster dose vaccination with Typhoid Vi Conjugate Vaccine of M/s Cadila Healthcare Limited in healthy subjects - None
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Cadila Healthcare Ltd
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Subjects who had participated and completed the previously conducted phase II/III clinical study (Project No. 15\-03\) and had received the study vaccine before 3 years ± 3 months
- •2\. Informed consent from adult subjects or from parents of the pediatric subjects. Additionally, assent from pediatric subjects of \>\=7 years of age
- •3\. Adult subjects or parents of pediatric subjects literate enough to fill the diary card
Exclusion Criteria
- •1\. History of typhoid fever or vaccination against typhoid fever after previous study
- •2\. Subjects administered blood, blood containing products or immunoglobulins during the past 3 months
- •3\. Clinically significant systemic disorder such as cardiovascular, respiratory, neurologic, gastrointestinal, hepatic, renal, endocrine, hematological or immunological disorder
- •4\. Subjects with confirmed or suspected immunosuppressive or immunodeficiency disorder; or subjects on any immunosuppressive or immunostimulant therapy
- •5\. Known case of thrombocytopenia or any coagulation disorder, or subjects on anticoagulation therapy
- •6\. Participation in another clinical trial in the past 3 months
- •7\. Subjects with history of alcohol or drug abuse in the past one year
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 4
A clinical trial to study the effect of Capmatinib in Indian patients with Metastatic NSCLC (MET exon 14 skipping mutation positive)CTRI/2022/05/042549ovartis Healthcare Pvt Ltd
Not yet recruiting
Phase 4
Clinical study of Alogliptin in Patients With Type 2 Diabetes MellitusHealth Condition 1: null- Type 2 Diabetes MellitusCTRI/2017/04/008410Takeda Pharmaceuticals India Pvt Ltd300
Recruiting
Phase 4
A clinical trial to study the effect of Alpelisib plus fulvestrant in Indian Patients with advanced or metastatic breast cancer (ABC or MBC) with a PIK3CA mutatioCTRI/2022/04/042205ovartis Healthcare Pvt Ltd
Active, not recruiting
Phase 1
Concentration of ofatumumab in the breast milk of lactating women with relapsing forms of multiple sclerosisCTIS2023-505283-11-00ovartis Pharma AG20
Active, not recruiting
Phase 4
Adapalene 0.3% - Benzoyl peroxide 2.5% gel in subjects with Moderate to Severe Acne VulgarisHealth Condition 1: L700- Acne vulgarisCTRI/2021/06/034069GALDERMA India Pvt Ltd